Table 2.
Clinical outcomes of patients with malignant hilar biliary obstruction according to the method of cholangiography.
| Air group (n = 23) | Contrast group (n = 24) | p value | |
|---|---|---|---|
| Technical success | 20/23 (87.0) | 21/24 (87.5) | >0.99 |
| Functional success | 19/20 (95.0) | 20/21 (95.2) | >0.99 |
| Procedure time after cholangiography (minute)* | 30 (24.5–41) | 25 (20–38) | 0.104 |
| Post-ERCP adverse events | 5/23 (21.7) | 8/23 (33.3) | 0.374 |
| Cholangitis | 1/23 (4.3) | 7/24 (29.2) | 0.048 |
| Pancreatitis | 3/23 (13.0) | 1/24 (4.2) | 0.348 |
| Perforation | 1/23 (4.3) | 0/24 (0) | 0.489 |
| Hospital day after procedure* | 6 (3–12) | 6 (2–9) | 0.645 |
| Total bilirubin after 1 month (mg/dl)* | 1.1 (0.8–1.8) | 1.0 (0.6–1.5) | 0.262 |
| 30-day stent occlusion$ | 2/20 (9.1) | 1/21 (4.8) | >0.99 |
| 30-day mortality | 2/23 (8.3) | 2/24 (8.7) | >0.99 |
*
Values are presented as median (interquartile range). Other values are presented as number (%).
$
Causes of stent occlusion were tumor ingrowth in all patients.
ERCP, endoscopic retrograde cholangiopancreatography.